Maintaining ERBB Blockade in EGFR-mutated Lung Cancer

NCT02488694 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped unsufficient recruitment

Conditions

Non-small-cell Lung Cancer With Somatic EGFR Mutations

Interventions

DRUG: Afatinib
DRUG: Pemetrexed

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]